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Abstract
Background Everolimus-related interstitial lung disease (ILD) (also: pneumonitis) poses a difficulty for physicians, as it is 
hard to discriminate ILD from other causes of respiratory symptoms and to decide on safe treatment continuation.
Objective We investigated the capability of pulmonary function tests (PFT), plasma biomarkers, everolimus pharmacokinet-
ics, and FDG-PET to discriminate between everolimus-related ILD and other causes of respiratory problems and to predict 
the severity of ILD.
Patients and methods Women starting treatment with everolimus plus exemestane for advanced breast cancer were included. 
At baseline and during the first 3 months, respiratory symptoms, PFT with diffusion capacity of the lungs for carbon monox-
ide corrected for hemoglobin (DLCOc) and forced vital capacity, serum plasma biomarkers (including SP-D and YKL-40), 
everolimus trough concentration, and 18F-FDG-PET were prospectively recorded.
Results Twenty-seven (out of 29 included) patients were evaluable for analysis. Fifteen patients (56%) developed everolimus-
related respiratory signs or symptoms and four patients (15%) needed everolimus discontinuation and received corticoster-
oids. Change in DLCOc differentiated ILD from alternative diagnoses with 0.91 sensitivity and 0.78 specificity. Decrease 
in DLCOc (non-significant) was greatest in patients who needed everolimus discontinuation. Serum SP-D and YKL-40 
could differentiate ILD from alternative diagnoses with 0.83 and 0.83 sensitivity, and 0.85 and 0.62 specificity, respectively. 
18F-FDG-PET abnormalities did not precede clinical symptoms. No relationship between ILD and everolimus trough con-
centration was found.
Conclusions This study shows that everolimus-related ILD occurs frequently. Prospective monitoring of DLCOc in combi-
nation with measurement of serum SP-D and YKL-40 appear useful to discriminate ILD from other causes of respiratory 
symptoms. Clinicaltrials.gov identifier: NCT01978171.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1152 3-019-00656 -2) contains 
supplementary material, which is available to authorized users.
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Key Points 
This is the first study to prospectively investigate drug-
induced interstitial lung disease and the value of diverse 
diagnostic biomarkers to discriminate ILD from alternate 
diagnoses.
Diffusion capacity and the plasma biomarkers YKL-40 
and SP-D can differentiate everolimus-induced ILD from 
alternate causes.
A rapid decrease in diffusion capacity could be an indi-
cation of severe ILD needing treatment discontinuation.
1 Introduction
In the past decades many novel anti-cancer agents including 
targeted therapies and immune checkpoint inhibitors have 
been developed, resulting in significant improvement of 
treatment outcomes [1, 2]. These new treatments are associ-
ated with specific toxicities, including pulmonary toxicities, 
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in the blood are known to predict or monitor the develop-
ment and severity of drug-induced ILD. Furthermore, it is 
not known whether there is an exposure-effect relationship 
in the development of everolimus-induced ILD, as the patho-
physiological mechanism of everolimus-induced ILD is not 
known.
A prospective analysis of any form of drug-induced ILD 
following patients from the start of treatment has not been 
performed yet. In the current study, we prospectively investi-
gated in ABC patients receiving everolimus plus exemestane 
whether PFT, plasma biomarkers, everolimus trough con-
centrations, and FDG-PET could discriminate everolimus-
induced ILD from other respiratory problems. Furthermore, 
we determined whether changes in PFT are indicative of the 
severity of ILD.
2  Methods
2.1  Patients
The present investigation (PREVENT study) was a prospec-
tive, open-label, observational, explorative study carried out 
in three hospitals in the Netherlands. The study protocol was 
approved by the Radboudumc ethics committee (reference 
number 2013-285) and all patients gave written informed 
consent. Clinicaltrials.gov identifier: NCT01978171.
We included postmenopausal women with ABC before 
the start of treatment with everolimus plus exemestane. 
Planned enrollment was 100 patients to guarantee the pres-
ence of enough cases of ILD. No formal power analysis 
was done as this was an exploratory study. Recruitment was 
considerably slower than anticipated due to reduced use of 
this treatment when data became available that no survival 
benefit was demonstrated. Furthermore, CDK4/6 inhibi-
tors became available as an alternative line of treatment. 
For this reason and considering the high frequency of ILD 
already observed in the study participants, the study was 
closed early.
2.2  Clinical Evaluation
Patients were evaluated at baseline and at days 14, 35, 60, 
90, and 120 after start of therapy. At each visit adverse 
events were recorded using the Common Terminology 
Criteria for Adverse Events (CTCAE), version 4.03. Using 
clinical symptoms, PFT, and imaging, patients were clas-
sified as having airway disease, suspected ILD, ILD, or an 
alternative diagnosis (Table 1), as described in detail pre-
viously [5]. In case of respiratory symptoms, infectious 
analysis was performed with chest X-ray, sputum culture, 
that require adequate management to prevent serious mor-
bidity and even mortality [3, 4]. Interstitial lung disease 
(ILD), or non-infectious pneumonitis, is an adverse event 
of special importance, as it is often hard to discriminate 
between different causes of respiratory symptoms as well 
as to decide on safe treatment continuation.
An anticancer drug that is associated with frequent occur-
rence of ILD is the mTOR inhibitor everolimus, with a 
reported incidence of ILD varying between 3 and 54% [5]. In 
a meta-analysis of 4,242 cancer patients treated with mTOR 
inhibitors, the incidence of any grade pneumonitis was 11%, 
any grade dyspnea 15%, and any grade cough 23% [6]. It 
is important to note that mTOR inhibitor-induced ILD can 
be very serious, as respiratory insufficiency and even fatal 
cases have been described [7–9]. mTOR inhibitor-induced 
ILD is suspected to be of immunological origin, possibly by 
exposure of cryptic antigens, delayed-type hypersensitivity, 
or by an increase in proinflammatory cytokines [10–13].
Everolimus plus exemestane is a valuable treatment 
option for patients with advanced breast cancer (ABC), but 
ILD is amongst the most common high-grade adverse events 
and is a frequent cause of treatment discontinuation [14–17]. 
In the BOLERO-2 trial, 10% of patients required everolimus 
dose interruption or reduction because of ILD [18].
Cough and dyspnea are reported frequently and may have 
several causes, including opportunistic infections such as 
Pneumocystis jirovecii pneumonia [19]. In patients with 
everolimus-induced ILD it is hard to predict whether or 
not treatment can be continued safely. Biomarkers leading 
to better recognition of ILD and to improved prediction of 
its severity are lacking, but would be of significant clinical 
value. Biomarkers that may contribute to this are pulmo-
nary function tests (PFTs), plasma biomarkers, everolimus 
pharmacokinetics, and  [18F]-fluorodeoxyglucose positron 
emission tomography with integrated computed tomogra-
phy (FDG-PET).Two small retrospective studies have shown 
an association between mTOR inhibitor-induced ILD and a 
decline in diffusing capacity of the lung for carbon monox-
ide (DLCO) [20, 21]. In other ILDs, plasma biomarkers such 
as surfactant protein A (SP-A), surfactant protein D (SP-D), 
CC16, CCL18, YKL-40, lactate dehydrogenase (LDH), and 
cancer antigen (CA) 15-3 correlate with pulmonary inflam-
mation [22–27]. Previous studies have demonstrated that a 
high everolimus trough concentration is associated with a 
higher risk of toxicity [14, 28]. Increased FDG-avidity in 
the lungs on FDG-PET scans has been reported in several 
patients with drug-induced ILD such as bleomycin, rituxi-
mab, etoposide, and paclitaxel, mostly as diffuse bilateral 
FDG-accumulation [29–35]. FDG-PET has been reported 
to detect ILD earlier than high resolution computed tomog-
raphy [36]. Therefore, this may be an early marker of ILD.
It is not known yet if PFT can discriminate ILD from 
other causes or can predict its severity. Also, no biomarkers 
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PCR for respiratory viruses, serology for atypical pneumo-
nia (Mycoplasma pneumoniae, Chlamydia psitacci), and 
legionella antigen test in urine. In case of possible oppor-
tunistic infection, a bronchoalveolar lavage for Pneumocystis 
jirovecii pneumonia was performed.
2.3  Pulmonary Function Tests (PFTs)
PFTs were performed according to ATS/ERS criteria at 
every scheduled visit until day 120 and additionally when 
respiratory symptoms occurred. Forced vital capacity (FVC 
in liters) and single breath diffusion capacity of the lungs for 
carbon monoxide (DLCO in mmol/min/kPa) were measured. 
DLCO was corrected for hemoglobin (DLCOc) [37].
2.4  Plasma Biomarkers
Blood was drawn at every scheduled visit until day 120 and 
at the occurrence of new respiratory symptoms. More infor-
mation on the measurements is provided in the Electronic 
Supplementary Methods. Considering the variation in abso-
lute values between individuals, the ratio of plasma biomark-
ers relative to the baseline value was used.
2.5  FDG‑PET and Pharmacokinetics
Patients could choose to participate in the FDG-PET imag-
ing part or not. FDG-PET was performed at baseline, day 
14, and day 35 after start of treatment. Scans were qualita-
tively judged by a nuclear medicine physician for FDG-avid 
abnormalities consistent with ILD. The temporal relation-
ship between FDG-abnormalities and clinical symptoms was 
evaluated.
Everolimus trough concentrations were measured in 
whole blood at day 14, 24 h after everolimus administra-
tion, by a validated liquid chromatography tandem mass 
spectrometry technique.
2.6  Statistics
To compare groups of patients, for each patient we used the 
PFT or plasma biomarker measurement at the first moment 
of the patient’s highest severity classification (ILD > sus-
pected ILD > alternative diagnosis > airway disease > no res-
piratory signs). For patients without respiratory symptoms, 
the value of PFT closest to the moment of median onset of 
ILD was used (day 65). Data were analyzed qualitatively, as 
described in the Electronic Supplementary Methods.
Using a Mann–Whitney U test, the change in PFT was 
compared between patients with everolimus-related (sus-
pected) ILD and patients with respiratory signs due to 
an alternative diagnosis. Using a Mann–Whitney U test, 
plasma biomarkers were compared between patients with 
(suspected) ILD and patients without respiratory symptoms, 
with airway disease, or with respiratory symptoms due to 
Table 1  Diagnostic classification of respiratory symptoms [5]
CTCAE Common Terminology Criteria for Adverse Events, PFT pulmonary function test, ILD interstitial lung disease, BAL bronchoalveolar 
lavage, DLCOc diffusion capacity of the lungs for carbon monoxide corrected for hemoglobin
a CTCAE pneumonitis NOT included
b Significant PFT decline defined as: DLCOc corrected for Hb decline ≥ 2 SD compared to baseline AND/OR FVC decline ≥ 2 SD compared to 
baseline
c Provided that other possible diagnoses are considered or excluded, such as pulmonary infection, congestive heart failure, pulmonary embolism, 
carcinomatous lymphangitis or pleuritis, radiation recall pneumonitis, asthma bronchiale, or gastroesophageal reflux
CTCAE  gradea (dyspnea, 
cough, fever)
PFT  declineb Chest CT parenchymal 
abnormalities
Infectious analysis Conclusionc
0 Non-significant Absent – No ILD
Present – Suspected ILD
Significant Absent General Inconclusive
Present General + consider BAL ILD
1 or 2 Non-significant Absent General Airway disease
Present General + consider BAL Suspected ILD
Significant Absent General + consider BAL Suspected ILD
Present General + BAL ILD
3 or 4 Non-significant Absent General + consider BAL Inconclusive
Present General + BAL ILD
Significant Absent General + BAL Inconclusive
Present General + BAL ILD
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other causes. A receiver-operating-characteristic (ROC) 
curve analysis was performed, with calculation of the area 
under the curve (AUC), and testing whether this AUC sig-
nificantly differed from 0.50. An optimal cut-off value was 
determined using the Youden index (value with highest sum 
of sensitivity + specificity – 1) [38]. Sensitivity, specificity, 
and negative and positive predictive value were calculated.
In patients with (suspected) ILD, the change in DLCOc 
and FVC at the first moment of the highest classification 
was compared between patients with and without the need 
for everolimus discontinuation. In patients who discontinued 
everolimus due to (suspected) ILD, it was visually evaluated 
whether discontinuation was preceded by a rise in plasma 
biomarkers.
As this was an exploratory and hypothesis-generating 
analysis, no correction for multiple testing was performed.
3  Results
3.1  Patients
Between April 2014 and October 2017, 29 subjects were 
enrolled. Almost all patients who were eligible for the study 
did participate in the study. Two patients were a screen fail-
ure (in one patient after informed consent it was decided to 
start a different treatment and in the other patient informed 
consent was withdrawn due to a decline of general wellbe-
ing), and 27 patients could be analyzed. Population demo-
graphics are described in Table 2.
3.2  Respiratory Symptoms
From the 27 patients included, 15 patients (56%) devel-
oped everolimus-related respiratory problems (symptoms 
or DLCOc or CT abnormalities): three patients were clas-
sified as ILD, 11 with suspected ILD (two patients were 
asymptomatic, but with CT abnormalities consistent with 
ILD), and one with airway disease. Eight patients (30%) 
had an alternative diagnosis (four progression of malignant 
pleural effusion, three suspected viral respiratory infection, 
one Pneumocystis jirovecii pneumonia). Four patients (15%) 
had no respiratory symptoms. Details of the classification 
are described in Electronic Supplementary Table 1.
Median time to onset of (suspected) ILD was 65 days 
(range 32–119). Four patients discontinued treatment 
because of (suspected) ILD and were treated according 
to protocol with prednisolone 60 mg/day followed by 
tapering, for a mean duration of 69 days (range 50–95) 
and everolimus was discontinued permanently. In three 
of these patients corticosteroids were started at the diag-
nosis of ILD and discontinuation of everolimus, and in 
one patient corticosteroids were started 10 days later. 
This resulted in clinical improvement in all cases. From 
the four patients who discontinued treatment because of 
(suspected) ILD, one patient had a history of pulmonary 
problems (asthma), one patient was a previous smoker, 
and one patient previously underwent radiation of the 
breast, but pulmonary abnormalities in this patient were 
bilateral. In these patients, there was a clear increase in 
pulmonary symptoms compared to baseline, therefore the 
symptoms were not attributable to an increase of the pre-
existent problems.
3.3  PFTs
Due to logistical reasons no PFTs were done in three 
patients at day 60 and in three patients at day 90. In the 
four patients who discontinued everolimus due to (sus-
pected) ILD, DLCOc was better correlated with ILD than 
FVC. In three out of these four patients, a ≥ 2 SD decrease 
in DLCOc preceded the diagnosis of ILD (Fig. 1). In two 
out of these four patients the PFT decline was considered 
significant according to the diagnostic protocol. No other 
patients had a significant PFT decline.
Table 2  Population demographics
Characteristic
Age (years; median and rage) 62 (35–76)
Race All Caucasian
Eastern Cooperative Oncology Group Performance Status score 
(n,  %)
 0 18/27 (67)
 1 8/27 (30)
 2 1/27 (4)
Follow-up time (days, median) 95
Current or ex-smokers (n) 8/27
History of pulmonary disease (n) 3
 Chronic obstructive pulmonary disease 1
 Asthma bronchiale 1
 Bronchiectases 1
History of radiation of the breast region (n,  %) 15/27 (56%)
Number of previous treatments (mean)
 In adjuvant setting 1.1
 In metastatic setting 2.1
 Total 3.2
 Lymphocyte count < 500/mm3 during treatment 1 patient at 
two time-
points
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3.3.1  PFTs to Discriminate (Suspected) Interstitial 
Lung Disease (ILD) from an Alternative Diagnosis 
in Patients with Respiratory Symptoms
The median decrease in FVC was 0.21L (8%) in the 14 
patients with everolimus-related (suspected) ILD, com-
pared to 0.20 L (6%) in the eight patients with respira-
tory symptoms due to an alternative cause (p = 0.328 and 
p = 0.328, respectively). DLCOc decrease was 1.02 mmol/
min/kPa (16%) in everolimus-related (suspected) ILD versus 
a 0.10 mmol/min/kPa increase (1%) in patients with other 
causes (p = 0.004 and p = 0.005, respectively) (Fig. 2). ROC 
analysis using the absolute decrease in DLCOc to predict 
(suspected) ILD showed an AUC of 0.90 (p = 0.003). At 
the optimal cut-off point of a 0.16 mmol/min/kPa decrease 
in DLCOc, this had a sensitivity of 0.92 and a specific-
ity of 0.86, with a positive and negative predictive value 
of 0.92 and 0.86, respectively. Alternatively, if a cut-off 
of a > 0.0 mmol/min/kPa DLCOc change is used to diag-
nose alternative causes and a > 1.0 mmol/min/kPa DLCOc 
decrease for (suspected) ILD, 67% of patients can be diag-
nosed and this is correct in 93% of cases.
3.3.2  PFTs to Predict the Need for Treatment 
Discontinuation in Patients with (Suspected) ILD
Patients with (suspected) ILD with the need for treat-
ment discontinuation showed a stronger DLCOc decrease 
compared to patients without the need for discontinuation 
(Fig. 3a, b), but this difference was not statistically signif-
icant. The median slopes of the 6 weeks before day zero 
were − 0.042 and − 0.00063, respectively. However, the 
DLCOc decrease was not statistically significantly dif-
ferent in patients with (-1.78 mmol/min/kPa, 27%) versus 
without (− 0.73 mmol/min/kPa, 14%) everolimus discon-
tinuation (p = 0.26 and p = 0.15, respectively). No signifi-
cant difference was observed in FVC decrease in patients 
with (0.21 L, 7%) or without everolimus discontinuation 
(0.19 L, 8%), (p = 0.70 and p = 0.94, respectively).
3.3.3  Correlation between Diffusion Capacity of the Lungs 
For Carbon Monoxide Corrected for Hemoglobin 
(DLCOc) Decrease and Severity of Respiratory 
Symptoms
In the total group of patients as well as in the group of 
patients with (suspected) ILD, no significant correlation 
Fig. 1  Pulmonary function tests in patients who discontinued everolimus due to (suspected) interstitial lung disease (ILD)
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was observed between the severity of symptoms and DLCOc 
decrease, Spearman r − 0.26 [95% confidence interval 
(CI) − 0.60, 0.16] and − 0.44 (95% CI − 0.80, 0.17).
3.4  Plasma Biomarkers
Plasma biomarkers were collected from 25 patients, with a 
total of 123 samples. Due to logistical problems, from two 
patients no samples could be collected and from the other 
25 patients, one sample on day 14 and two samples on day 
35 were not collected. One sample had to be discarded due 
to pre-analytical errors.
3.4.1  Plasma Biomarkers to Discriminate Between Patients 
With and Without (Suspected) ILD
Patients with (suspected) ILD were compared to patients 
without respiratory symptoms, airway disease, or respira-
tory symptoms due to an alternative cause. Concentrations 
of YKL-40 and SP-D in patients with (suspected) ILD were 
significantly higher compared to patients without (suspected) 
ILD (Table 2), median ratio 1.31 versus 0.94 and 1.27 versus 
0.64, respectively. No significant difference between the ILD 
and no-ILD group was seen regarding CA 15-3, uteroglobin, 
CCL18, SP-A, and LDH concentrations. YKL-40 and SP-D 
showed the highest ROC AUC. At the optimal cut-off points 
(> 1.10 and > 1.00, respectively), these plasma biomarkers 
had high sensitivity and specificity and positive and negative 
predictive values (Table 3).
The optimal cut-offs for DLCOc and SP-D were com-
bined, and patients were classified as with or without (sus-
pected) ILD when both tests indicated the same direction. 
This could classify 70% of patients, with positive and nega-
tive predictive values of 1.0 and 0.80, respectively.
3.4.2  Plasma Biomarkers to Predict the Need for Treatment 
Discontinuation in Patients with (Suspected) ILD
In three out of four patients who discontinued everolimus 
treatment due to ILD, plasma biomarker data were available. 
In these three patients, changes in concentration of plasma 
biomarkers SP-A, SP-D, and YKL-40 paralleled the devel-
opment of ILD best (Fig. 4). However, plasma biomarker 
concentrations did not allow discrimination between patients 
with and without the need for treatment discontinuation. In 
patients with (suspected) ILD, the median ratio of YKL-40 
Fig. 2  Change in DLCOc at the 
first moment of the patient’s 
highest severity classifica-
tion compared to baseline per 
classification in patients with 
respiratory symptoms. Each bar 
represents one patient
Fig. 3  Spaghetti plots of DLCOc for patients with (suspected) interstitial lung disease (ILD) with versus without the need for discontinuation
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was 1.29 in patients without the need for discontinuation, 
compared to 1.32 in the patients with the need for discon-
tinuation (p = 1.00). For SP-D, medians were 1.09 and 1.52, 
respectively (p = 0.11).
3.5  Everolimus Pharmacokinetics
Everolimus trough concentrations were measured in 26 
patients. There was no difference in everolimus concen-
trations of patients with versus without (suspected) ILD, 
with geometric mean concentrations of 10.3 and 10.1 µg/L, 
respectively (p = 0.94).
3.6  FDG‑PET
Four patients did not participate in the FDG-PET imaging 
part, and therefore FDG-PET data were available from 11/15 
patients with everolimus-related respiratory symptoms. 
From these patients, none had enhanced FDG uptake at day 
14, while 7/11 patients showed an FDG-uptake pattern con-
sistent with ILD on day 35. In these patients, FDG-uptake 
was most often focal consolidations, either unilateral or 
bilateral. From these seven patients with respiratory symp-
toms and FDG-PET abnormalities, six patients were clas-
sified as (suspected) ILD at or before day 35. The seventh 
patient showed pulmonary abnormalities consistent with 
ILD at day 35 and developed suspected ILD at day 89. As 
such, FDG-PET abnormalities mostly did not precede the 
clinical diagnosis. No enhanced FDG uptake was seen in 
patients without everolimus-related respiratory symptoms.
4  Discussion
To the best of our knowledge, this is the first prospective 
study investigating drug-induced ILD. We demonstrated that 
in ABC patients treated with everolimus, DLCOc decline 
and the plasma biomarkers YKL-40 and SP-D seem to dis-
criminate patients with versus without (suspected) ILD. 
DLCOc shows a much better diagnostic performance for 
detecting ILD than FVC. The amount of DLCOc decline 
seems to be different for (suspected) ILD and alternative 
causes, such as malignant pleural effusion and respiratory 
infections. However, as DLCOc is foremost a marker of dis-
ease severity, analysis in more patients is needed to confirm 
the discriminative capability of DLCOc. A rapid decrease in 
absolute DLCOc could be an alarming indicator for severe 
toxicity necessitating treatment discontinuation. Further-
more, this study shows that the grade of respiratory symp-
toms is not a good reflection of the decrease in diffusion 
capacity. As such, measurement of DLCOc could be used 
as an indication of the severity of parenchymal changes. As 
the change in PFT compared to baseline is more informa-
tive than the absolute value, PFT is preferably performed at 
baseline and during follow-up.
SP-D is a protein involved in pulmonary immune and 
inflammatory regulation and in surfactant homeostasis, and 
has previously shown its value in hypersensitivity pneu-
monitis and idiopathic pulmonary fibrosis [39–41]. YKL-
40 is involved in tissue remodeling after an inflammatory 
response and has been associated with idiopathic pulmonary 
fibrosis, sarcoidosis, and hypersensitivity pneumonitis [42]. 
However, YKL-40 is also known to be associated with breast 
cancer markers [43]. We demonstrate that these proteins also 
increase in drug-induced ILD. SP-A, uteroglobin, CCL18, 
and LDH showed a non-significant increase in everolimus-
induced ILD.
No correlation was seen between everolimus trough con-
centration and the development of (suspected) ILD, whereas 
other everolimus-related toxicities have been related to 
trough concentration [14, 28]. This observation is in line 
with other studies that have indicated that the development 
of ILD is not exposure-related [44, 45]. Most patients with 
(suspected) ILD had FDG-avid pulmonary abnormalities. 
Table 3  Diagnostic performance of change of plasma biomarkers from baseline to discriminate patients with and without (suspected) interstitial 
lung disease (ILD)
ROC receiver-operating characteristic
Plasma biomarker Median ratio for 
patients without (sus-
pected) ILD (n = 13)
Median ratio for 
patients with (sus-
pected) ILD (n = 12)
p value Area under 
the ROC 
curve
Sensitivity Specificity Positive 
predictive 
value
Negative 
predictive 
value
YKL-40 0.94 1.31 0.039 0.75 0.83 0.62 0.67 0.80
SP-D 0.64 1.27 0.003 0.85 0.83 0.85 0.83 0.85
SP-A 1.07 1.63 0.077 0.71
Uteroglobin 1.23 1.29 0.849 0.53
CCL18 0.27 0.38 0.231 0.64
CA 15.3 1.19 1.02 0.479 0.59
LDH 1.37 1.47 0.735 0.55
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However, as these FDG-PET abnormalities mostly did not 
precede the clinical symptoms, FDG-PET does not seem to 
have significant predictive value for ILD.
The incidence of ILD was high, as 56% of patients devel-
oped everolimus-related respiratory problems, and 15% had 
to discontinue treatment because of drug-induced ILD. This 
high incidence is in contrast with earlier studies, such as 
the BOLERO-2 [16], which demonstrates that the incidence 
of ILD is higher when awareness is high. Furthermore, it 
illustrates that the incidence of ILD is very variable as 
there are no generally accepted criteria for its diagnosis. It 
is important to note that patients with CT abnormalities or 
a DLCOc decrease may have no or only minor symptoms 
and the majority of patients with suspected ILD continued 
everolimus without further deterioration. Everolimus dis-
continuation and treatment with prednisolone resulted in 
Fig. 4  Plasma biomarkers in 
patients who discontinued 
everolimus due to (suspected) 
interstitial lung disease (ILD)
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good recovery of symptoms and PFT in our patients with 
severe ILD.
The strong point of this study is the prospective collec-
tion of a comprehensive dataset. A prospective study of 
drug-induced ILD following patients from start of treat-
ment has not been published before. A limitation of this 
study is the limited sample size. Despite this, however, clear 
observations could be made because of the high incidence 
of everolimus-induced ILD. Another limitation is that as 
yet the diagnosis of drug-induced ILD is largely made per 
exclusion. In patients with respiratory symptoms, analysis 
for viral, bacterial, and yeast infections was performed on 
clinical suspicion and therefore was not performed in all 
patients. As such, it is possible that cases have been assessed 
as ILD when an alternative diagnosis was missed. Also, 
the criteria we used have not yet been externally validated. 
However, to date, no validated criteria exist. The criteria we 
used are detailed and use multiple sources of information. 
Therefore, we believe this is preferable above for instance 
the CTCAE criteria, which are very non-specific. Further-
more, we acknowledge the risk that PFT is not a fully inde-
pendent biomarker, as a significant PFT decline is part of the 
diagnostic criteria for ILD. However, only two patients had 
a significant PFT decline and patients were only diagnosed 
with ILD if other causes were excluded. In this study everoli-
mus was used in combination with exemestane. Exemestane 
is not associated with ILD [46], and therefore this does not 
seem to influence ILD incidence.
Our data should be considered explorative and hypoth-
esis-generating. Although our results will have to be con-
firmed in another study, we do suggest that a rise in SP-D 
combined with a decrease in DLCOc (> 0.16 mmol/min/kPa) 
is suggestive of everolimus-induced lung injury. DLCOc and 
plasma biomarker measurements could be useful in monitor-
ing other forms of drug-induced ILD, especially for targeted 
therapies such as PI3 K inhibitors and Akt inhibitors, with 
similar class-related pneumonitis. However, the use of the 
biomarkers identified in our study need to be confirmed for 
these other anticancer therapies.
In summary, we report a high incidence of everolimus-
related ILD and have prospectively shown that DLCOc and 
SP-D and YKL-40 provide valuable tools for the early diag-
nosis of everolimus-induced lung toxicity. If after validation 
these tests can be applied in a clinical algorithm this could 
help to keep patients on treatment when possible, while also 
preventing drug-induced morbidity.
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